David Scott Miller, Professor and Chief of the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology, leads the team of gynecologic oncologists at UT Southwestern. He is Medical Director for the Division's practice at the NCI-designated Harold C. Simmons Cancer Center.
Dr. Miller also serves as principal investigator for the National Cancer Institute’s Gynecologic Oncology Group program at UT Southwestern and participates in the cancer treatment protocols developed by that organization.
A graduate of the University of Oklahoma College of Medicine, Dr. Miller completed his residency in obstetrics and gynecology at the Hospital of the Medical College of Pennsylvania. After residency, he pursued a reproductive endocrinology fellowship at the University of California-San Diego and a gynecologic oncology fellowship at Stanford University Medical Center. Before joining the faculty at UT Southwestern in 1991, he practiced gynecologic oncology at Northwestern University Medical School in Chicago.
Widely-known as an authority on cancers of the female reproductive system, Dr. Miller is board certified in both obstetrics and gynecology and gynecologic oncology. He serves as an examiner for the American Board of Obstetrics and Gynecology, where he participates in the oral examination of physicians seeking certification as specialists in gynecologic oncology. He is a member of the Society of Gynecologic Oncologists, American Society of Clinical Oncology, American Congress of Obstetricians and Gynecologists, and the American College of Surgeons.
Dr. Miller believes the gynecologic oncology team’s strength comes from its collaborative approach to health care and commitment to search for the best treatment options for women with cancer of the reproductive system. This approach goes beyond treatment of the cancer itself to include the patient’s nutrition and pain management as well as psychological and social adjustments.
- Medical School
- University of Oklahoma at Tulsa (1977)
- Medical College of Pennsylvania (1978), Obstetrics & Gynecology
- Medical College of Pennsylvania (1981), Obstetrics & Gynecology
- University of California at San Diego (1982), Gynecologic Oncology
- Stanford University Hospital (1985), Gynecologic Oncology
- Antineoplastic drug development
- Clinical trials
- Gynecologic Oncology
- Reconstructive pelvic surgery
- Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
- Miller DS, Blessing JA, Schilder J, Munkarah A, Lee YC Gynecol. Oncol. 2005 Aug 98 2 217-21
- Fertility-sparing surgery for ovarian low malignant potential tumors.
- Rao GG, Skinner EN, Gehrig PA, Duska LR, Miller DS, Schorge JO Gynecol. Oncol. 2005 Aug 98 2 263-6
- Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study
- Long HJ 3rd. Bundy BN. Grendys EC Jr. Benda JA. McMeekin DS. Sorosky J. Miller DS. Eaton LA. Fiorica JV. Journal of Clinical Oncology July 2005 23(21) 4626-33
- Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
- Long HJ, Bundy BN, Grendys EC, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV J. Clin. Oncol. 2005 Jul 23 21 4626-33
- Duration of human chorionic gonadotropin surveillance for partial hydatidiform moles.
- Lavie I, Rao GG, Castrillon DH, Miller DS, Schorge JO Am. J. Obstet. Gynecol. 2005 May 192 5 1362-4
- Clinical applications of hormonal therapy in ovarian cancer.
- Rao GG, Miller DS Curr Treat Options Oncol 2005 Mar 6 2 97-102
- Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
- Garcia AA, Blessing JA, Lenz HJ, Darcy KM, Mannel RS, Miller DS, Husseinzadeh N Gynecol. Oncol. 2005 Mar 96 3 810-7
- Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
- Miller DS, Blessing JA, Waggoner S, Schilder J, Sorosky J, Bloss J, Schilder R Gynecol. Oncol. 2005 Jan 96 1 67-71
- Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study
- Moore DH. Blessing JA. McQuellon RP. Thaler HT. Cella D. Benda J. Miller DS. Olt G. King S. Boggess JF. Rocereto TF. Journal of Clinical Oncology August 2004 22(15) 3113-9
- Intraoperative lymphatic mapping in cervix cancer patients undergoing radical hysterectomy: A pilot study
- O’Boyle, J.D., Coleman, R.L., Bernstein, S.G., Lifshitz, S., Muller, C.Y., Miller, D.S. Gynecologic Oncology 2000 79 (2) 238-243
Honors & Awards
- Super Doctors in Texas - Oncology
Oncology; Obstetrics/Gynecology (2013)
- Top Doctor - Gynecologic Oncology / Gynecology
U.S. News and World Report (2013)
- D Best - Gynecological Oncology
D Magazine Best Doctors 2010, 2011 (2012)
- Texas Super Doctors
Texas Monthly (2011)
- National Faculty Award
Council on Resident Education in Obstetrics & Gynecology (2000)
- Senior Residents Award for Outstanding Faculty Teacher
Department of Obstetrics & Gynecology, University of Texas Southwestern Medical Center at Dallas (2000)
- First Prize Scientific Paper Award
American College of Obstetricians & Gynecologists, 39th Annual Meeting (1991)
- D Best Doctor - Gynecological Oncology
D Magazine - 2012, 2011, 2010
- American College of Obstetricians & Gynecologists
- American College of Surgeons
- American Society of Clinical Oncology
- Gynecologic Oncology Group
- Society of Gynecologic Oncology